4-氨基-2,6-二甲基苯甲醛 | 63405-90-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-2,6-二甲基苯甲醛
• 中文别名: 苯甲醛,4-氨基-2,6-二甲基
• 英文名称: 4-amino-2,6-dimethylbenzaldehyde
• CAS: 63405-90-3
• 化学式: C₉H₁₁NO
• mdl: MFCD18824455
• 分子量: 149.192
• InChiKey: RYOVQGPPVBEYFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2922399090

反应信息

• 作为反应物：
  描述：

  4-氨基-2,6-二甲基苯甲醛 在 tetrafluoroboric acid 、 palladium 10% on activated carbon 、 氢气 、 ytterbium(III) triflate 、 sodium nitrite 作用下， 以 二氯甲烷 、 水 、 二甲基亚砜 为溶剂， 80.0 ℃ 、101.33 kPa 条件下， 反应 79.0h， 生成 3-{4-[6-(3,4-dimethylphenylcarbamoyl)-1H-benzoimidazol-2-yl]-3,5-dimethylphenyl}propionic acid methyl ester
  参考文献：
  名称：

  Intestinally Targeted Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitors Robustly Suppress Postprandial Triglycerides

  摘要：

  High DGAT1 expression levels in the small intestine highlight the critical role this enzyme plays in nutrient absorption. Identification of inhibitors which predominantly inhibit DGAT1 in the gut is an attractive drug discovery strategy with anticipated benefits of reduced systemic toxicity. In this report we describe our discovery and optimization of DGAT1 inhibitors whose plasma exposure is minimized by the action of transporters, including the P-glycoprotein transporter. The impact of this unique absorption profile on efficacy in rat and dog efficacy models is presented.

  DOI：

  10.1021/ml3000512
• 作为产物：
  描述：

  4-氨基-3-硝基苯甲酸 在 sodium hydroxide 、 水 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 4-氨基-2,6-二甲基苯甲醛
  参考文献：
  名称：

  WO2008/73865

  摘要：

  公开号：

文献信息

• [EN] OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE ET D'INDOLE SUBSTITUÉS PAR DE L'OXADIAZOLE ET OXAZOLE COMME INHIBITEURS DE DGAT1
  申请人：NOVARTIS AG

  公开号：WO2009040410A1

  公开（公告）日：2009-04-02

  The present invention provides oxadiazolyl- substituted benzimidazole- and idole-derivates that are useful for treating conditions or disorders associated with DGAT1 activity in animals, particularly humans.

  本发明提供了一种对氧代二唑基取代的苯并咪唑和吲哚衍生物，用于治疗与动物，特别是人类的DGAT1活性相关的疾病或疾病。
• ORGANIC COMPOUNDS
  申请人：Sung Moo Je

  公开号：US20110046133A1

  公开（公告）日：2011-02-24

  The present invention provides compounds of the following structure; A-L1-B-C-D that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.

  本发明提供了以下结构的化合物；A-L1-B-C-D，这些化合物对于治疗或预防与动物（尤其是人类）中DGAT1活性相关的疾病或疾病非常有用。
• Synthesis and Characterization of New Aromatic Polyesters Derived from New Aromatic Di- and Tri Hydroxyl Monomers with 4-Phenylenediacrylic Acid and Malonic Acid
  作者：Mohammed A. Mutar

  DOI：10.14233/ajchem.2014.18082

  日期：——

  In the present work, six new aromatic polyesters (PE1-PE6) have been synthesized in high yields from the polycondensation between di- and tri hydroxyl monomers containing methylene unit, Schiff-base linkages and pyridine heterocyclic ring with 4-phenylenediacrylic acid and malonic acid using dibutyltin dilaurate as catalyst. The structure analysis of the polymers has been carried out by using FT-IR and 1H NMR spectroscopy. The monomers were characterized by FTIR and 1H NMR. FT-IR technique confirmed the esterification of di and tri hydroxyl monomers by the acid in all the polymers.

  本研究以二月桂酸二丁基锡为催化剂，将含有亚甲基单元、席夫碱链节和吡啶杂环的二羟基和三羟基单体与对苯二甲酸和丙二酸缩聚，高产合成了六种新型芳香族聚酯（PE1-PE6）。聚合物的结构分析是通过傅立叶变换红外光谱和 1H NMR 光谱进行的。傅立叶变换红外光谱和 1H NMR 对单体进行了表征。傅立叶变换红外光谱技术证实，所有聚合物中的二羟基和三羟基单体都被酸酯化。
• Novel Cercosporamide Derivative
  申请人：Furukawa Akihiro

  公开号：US20090036492A1

  公开（公告）日：2009-02-05

  The present invention relates to a novel cercosporamide derivative, a pharmacologically acceptable salt thereof or an ester thereof which has an excellent hypoglycemic effect and is useful as a therapeutic and/or prophylactic agent for diabetes. A cercosporamide derivative having the general formula (I): [wherein X represents an oxygen atom or the like, R 1 represents a hydrogen atom or a C 1 -C 6 alkyl group, R 2 represents a hydrogen atom, a C 1 -C 6 alkyl group or a C 1 -C 6 halogenated alkyl group, R 3 represents a hydrogen atom or a C 1 -C 6 alkyl group, R 4 represents a C 6 -C 10 aryl group which may be substituted with one to five group(s) independently selected from Substituent Group a, or the like, n represents 1, 2 or 3, and Substituent Group a represents a halogen atom, a C 1 -C 6 alkyl group, a C 1 -C 6 halogenated alkyl group, a C 2 -C 6 alkenyl group, a C 2 -C 6 alkynyl group, a C 1 -C 6 alkoxy group, a C 1 -C 6 halogenated alkoxy group, a C 2 -C 6 alkenyloxy group, a C 2 -C 6 alkynyloxy group and the like], a pharmacologically acceptable salt thereof or an ester thereof.

  本发明涉及一种新型的环孢霉素衍生物，其具有优异的降血糖作用，可作为糖尿病治疗和/或预防制剂使用的药物学上可接受的盐或酯。 具有以下通式（I）的环孢霉素衍生物： [其中，X代表氧原子或类似物，R1代表氢原子或C1-C6烷基，R2代表氢原子、C1-C6烷基或C1-C6卤代烷基，R3代表氢原子或C1-C6烷基，R4代表C6-C10芳基，该芳基可被一个到五个独立选择的取代基a取代，n代表1、2或3，取代基a代表卤原子、C1-C6烷基、C1-C6卤代烷基、C2-C6烯基、C2-C6炔基、C1-C6烷氧基、C1-C6卤代烷氧基、C2-C6烯氧基、C2-C6炔氧基等]，其药学上可接受的盐或酯。
• METHOD OF TREATMENT
  申请人：Bose Avirup

  公开号：US20100016387A1

  公开（公告）日：2010-01-21

  Method of preventing or treating myocardial ischemia by inhibiting DGAT1 enzyme with a DGAT1 inhibitor compound.

  通过使用DGAT1抑制剂化合物来抑制DGAT1酶，预防或治疗心肌缺血的方法。